Connection

DON LYNN GIBBONS to Signal Transduction

This is a "connection" page, showing publications DON LYNN GIBBONS has written about Signal Transduction.
Connection Strength

0.466
  1. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells. 2019 12 24; 9(1).
    View in: PubMed
    Score: 0.049
  2. A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer. Sci Rep. 2019 03 20; 9(1):4819.
    View in: PubMed
    Score: 0.046
  3. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.
    View in: PubMed
    Score: 0.044
  4. TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun. 2018 07 16; 9(1):2731.
    View in: PubMed
    Score: 0.044
  5. Fibroblast-specific inhibition of TGF-?1 signaling attenuates lung and tumor fibrosis. J Clin Invest. 2017 Oct 02; 127(10):3675-3688.
    View in: PubMed
    Score: 0.041
  6. Musashi-2 (MSI2) supports TGF-? signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016 06 21; 113(25):6955-60.
    View in: PubMed
    Score: 0.038
  7. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42.
    View in: PubMed
    Score: 0.037
  8. The microRNA-200/Zeb1 axis regulates ECM-dependent ?1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep. 2016 Jan 05; 6:18652.
    View in: PubMed
    Score: 0.037
  9. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep. 2023 09 26; 42(9):113067.
    View in: PubMed
    Score: 0.016
  10. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023 04 03; 29(7):1292-1304.
    View in: PubMed
    Score: 0.015
  11. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.
    View in: PubMed
    Score: 0.014
  12. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep. 2021 04 20; 35(3):109009.
    View in: PubMed
    Score: 0.013
  13. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 2020 09; 91-92:8-18.
    View in: PubMed
    Score: 0.013
  14. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nat Commun. 2018 07 16; 9(1):2732.
    View in: PubMed
    Score: 0.011
  15. Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res. 2018 05 01; 24(9):2182-2193.
    View in: PubMed
    Score: 0.011
  16. Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun. 2017 08 04; 8(1):199.
    View in: PubMed
    Score: 0.010
  17. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012 Sep; 122(9):3170-83.
    View in: PubMed
    Score: 0.007
  18. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011 Dec 15; 71(24):7670-82.
    View in: PubMed
    Score: 0.007
  19. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011 Apr; 121(4):1373-85.
    View in: PubMed
    Score: 0.007
  20. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011 Mar 10; 364(10):947-55.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.